IL1B and atherosclerosis: IL-1β, a therapeutic target in atherosclerosis and other cardiovascular diseases, signals through JNK and NF-κB and inhibition of IL-1β may decrease the production of MMP3, SMC chemotaxis, and inflammasome-mediated inflammation [43,44].